Can you take Wegovy after bariatric surgery?

Is there clinical evidence for using Wegovy after weight-loss surgery?

The honest answer is: some, but not enough to give firm universal guidance. The large STEP 1 trial (published in the New England Journal of Medicine) established semaglutide's weight-loss profile in adults with obesity who had not undergone bariatric procedures, producing around 15% average body-weight reduction at 68 weeks. Post-bariatric patients were not the focus, so the headline figures do not straightforwardly translate.

What smaller studies and clinical case series do suggest is that semaglutide can help people who experience weight regain years after surgery, a recognised and distressing outcome that affects a substantial proportion of patients. Gastric bypass surgery already raises endogenous GLP-1 levels, which is one of the reasons it works so well in the first place. Adding an exogenous GLP-1 agonist on top of that altered physiology is plausible, but the interactions are complex enough that dosing, tolerability and monitoring all need specialist input.

The NHS England guidance on weight-management injections does not explicitly exclude post-bariatric patients, but it also does not provide a specific protocol for them. NICE's appraisal of semaglutide (Wegovy) recommends it within specialist weight management services for defined groups, the bariatric-surgery population is a specific subset that warrants specialist review rather than a standard online pathway.

If you had surgery within the last few months, most clinicians would advise stabilising first before introducing any new medicine. If your surgery was years ago and your weight has crept back, that is the scenario where GLP-1 treatment is most actively discussed.

Does the type of bariatric procedure change what is possible?

Yes, and this is one of the key reasons post-bariatric prescribing requires specialist assessment rather than a general eligibility check. The three most common procedures in the UK (Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric band) each produce different anatomical and hormonal changes.

With a gastric bypass, the rerouting of the small intestine already drives a significant rise in native GLP-1 secretion. Introducing semaglutide alongside that altered physiology is theoretically reasonable, but it also means the GI side-effect profile (nausea, vomiting, gastric slowing) may be more pronounced than in someone who has not had surgery. Absorption of oral medicines can also behave differently after bypass; though Wegovy is a subcutaneous injection so absorption is unaffected by gut anatomy, the interaction with gut motility still matters clinically.

Sleeve gastrectomy preserves more of the stomach's pyloric function, so the hormonal picture is different again. Band patients have yet another physiology. There is no single rule that covers all three.

Details on how surgical status affects prescribing decisions are covered in more depth on the surgery and Wegovy overview, which is worth reading alongside this page. For anyone weighing up the timing of a planned procedure, what happens if you are on Wegovy before surgery is a separate and important question.

What should you actually do if you want to explore this option?

Start with your bariatric team. If you are still under follow-up from your original surgery (and most units encourage long-term contact) raise the question at your next review. Your bariatric surgeon or specialist dietitian will know your surgical history, your current nutritional status and your weight trajectory, all of which shape whether Wegovy is a sensible addition.

If your bariatric follow-up has lapsed, your GP is the right first port of call. They can refer you back into specialist care or, where locally available, into a tier 3 weight management service that can make this assessment properly. NHS guidance on obesity treatment sets out what those pathways look like.

You can also read a fuller picture of how Wegovy works as a starting point before that conversation. If you are considering a private consultation, a responsible prescribing service will flag your surgical history and refer you to your specialist if there is any uncertainty, that is the appropriate response, not a reason to avoid disclosing it. Our prescribers at nume review every consultation personally; if your case needs specialist input before treatment can safely proceed, they will tell you clearly. You can check your eligibility through a free consultation and the clinical picture will determine the next step.

One practical habit worth building now: before any consultation, note the date of your surgery, the procedure name, your current BMI and any nutritional supplements you take. That information takes under a minute to gather from your discharge letter and saves significant back-and-forth. For anyone curious about how post-surgical considerations interact with stopping or starting treatment around future procedures, guidance on stopping Wegovy before surgery covers the relevant clinical reasoning.

Are pregnancy, breastfeeding or conception affected by this combination?

Wegovy is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, and that applies regardless of surgical history. The prescribing guidance is clear on this, and it does not change because you have had bariatric surgery. Bariatric surgery itself is associated with improved fertility, particularly in women with obesity-related hormonal conditions, so the question of contraception is especially relevant in the months after a procedure when weight is falling rapidly.

If you are considering pregnancy after weight-loss surgery and wondering how Wegovy fits in, the detail on pregnancy after Wegovy is a useful starting point, and Wegovy and pregnancy covers the broader picture. These pages point you towards the conversations to have with your GP and your bariatric team rather than trying to substitute for them. Stopping the medicine in good time before conception is part of safe clinical planning, exactly when that should happen is a question for your prescriber.